Invivyd (IVVD) Enters $75M Share Sale Agreement

On December 22, 2023, Invivyd (NASDAQ: IVVD) entered into a Controlled Equity OfferingSM Sales Agreement (the “Sales Agreement”) with Cantor Fitzgerald & Co., as sales agent (“Cantor”), pursuant to which the Company may offer and sell, from time to time, through Cantor, shares of the Company’s common stock, par value $0.0001 per share (the “Shares”). The offering and sale of up to $75.0 million of the Shares pursuant to the Sales Agreement is being registered under the Securities Act of 1933, as amended (the “Securities Act”), pursuant to the Company’s shelf registration statement on Form S-3 (File No. 333-267643), which was declared effective by the Securities and Exchange Commission (“SEC”) on October 5, 2022, which includes a base prospectus, and an accompanying prospectus supplement filed with the SEC on December 22, 2023.

Subject to the terms and conditions of the Sales Agreement, Cantor will use its commercially reasonable efforts to sell the Shares from time to time, based upon the Company’s instructions. The Company provided Cantor with customary indemnification rights, and Cantor will be entitled to a commission of 3.0% of the gross proceeds from each sale of the Shares. In addition, the Company agreed to reimburse certain expenses incurred by Cantor in connection with the Sales Agreement.

Sales of the Shares, if any, under the Sales Agreement may be made in transactions that are deemed to be “at the market offerings” as defined in Rule 415(a)(4) under the Securities Act. The Company has no obligation to sell any of the Shares and may at any time suspend offers under the Sales Agreement or terminate the Sales Agreement.

You May Also Be Interested In

• Matinas BioPharma to merge with GH Power, sell drug unit to Azurity
• Alto Neuroscience prices $100M stock offering to fund depression trial
• Banzai prices $0.9M public offering at $2.75 per share